Contrasting Mangoceuticals (MGRX) and Its Competitors

Mangoceuticals (NASDAQ:MGRXGet Free Report) is one of 21 publicly-traded companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it compare to its rivals? We will compare Mangoceuticals to related businesses based on the strength of its institutional ownership, valuation, dividends, profitability, earnings, risk and analyst recommendations.

Profitability

This table compares Mangoceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mangoceuticals -1,053.93% -243.34% -200.73%
Mangoceuticals Competitors -742.83% -44.76% -34.17%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Mangoceuticals and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mangoceuticals 0 0 0 0 N/A
Mangoceuticals Competitors 39 311 467 150 2.75

As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 48.45%. Given Mangoceuticals’ rivals higher probable upside, analysts clearly believe Mangoceuticals has less favorable growth aspects than its rivals.

Risk and Volatility

Mangoceuticals has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500. Comparatively, Mangoceuticals’ rivals have a beta of 3.73, suggesting that their average share price is 273% more volatile than the S&P 500.

Insider and Institutional Ownership

56.7% of Mangoceuticals shares are owned by institutional investors. Comparatively, 61.8% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by institutional investors. 39.3% of Mangoceuticals shares are owned by insiders. Comparatively, 28.0% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Mangoceuticals and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Mangoceuticals $730,000.00 -$9.21 million -0.38
Mangoceuticals Competitors $2.35 billion $61.83 million 14.05

Mangoceuticals’ rivals have higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Mangoceuticals rivals beat Mangoceuticals on 9 of the 10 factors compared.

Mangoceuticals Company Profile

(Get Free Report)

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.

Receive News & Ratings for Mangoceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mangoceuticals and related companies with MarketBeat.com's FREE daily email newsletter.